{"id":"https://openalex.org/W2472978162","doi":"https://doi.org/10.1212/wnl.0000000000002864","title":"Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies","display_name":"Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies","alternate_titles":[],"publication_year":2016,"publication_date":"2016-06-23","ids":{"openalex":"https://openalex.org/W2472978162","doi":"https://doi.org/10.1212/wnl.0000000000002864","mag":"2472978162","pmid":"https://pubmed.ncbi.nlm.nih.gov/27335114","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4955277"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.0000000000002864","doi":"https://doi.org/10.1212/wnl.0000000000002864","is_oa":true,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000002864","pdf_url":"https://n.neurology.org/content/neurology/87/3/314.full.pdf","source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2472978162"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://n.neurology.org/content/neurology/87/3/314.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061862920","display_name":"Elinor Ben\u2010Menachem","orcid":"https://orcid.org/0000-0001-5864-9185","observed_orcids":["https://orcid.org/0000-0001-5864-9185"]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]},{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]},{"id":"https://openalex.org/I881427289","display_name":"University of Gothenburg","ror":"https://ror.org/01tm6cn81","country_code":"SE","type":"education","lineage":["https://openalex.org/I881427289"]}],"countries":["GB","SE","US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Elinor Ben-Menachem","raw_affiliation_strings":["Institute for Clinical Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden","UCB Pharma (B.M.), Slough, UK","UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute for Clinical Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden","institution_ids":["https://openalex.org/I881427289"]},{"raw_affiliation_string":"UCB Pharma (B.M.), Slough, UK","institution_ids":["https://openalex.org/I4210134054"]},{"raw_affiliation_string":"UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076537689","display_name":"R\u016bta Mameni\u0161kien\u0117","orcid":"https://orcid.org/0000-0001-5719-8175","observed_orcids":["https://orcid.org/0000-0001-5719-8175"]},"institutions":[{"id":"https://openalex.org/I173212132","display_name":"Vilnius University","ror":"https://ror.org/03nadee84","country_code":"LT","type":"education","lineage":["https://openalex.org/I173212132"]},{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]},{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]},{"id":"https://openalex.org/I4210161607","display_name":"Vilnius University Hospital Santariskiu Klinikos","ror":"https://ror.org/0590pq693","country_code":"LT","type":"healthcare","lineage":["https://openalex.org/I4210161607"]}],"countries":["GB","LT","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"R\u016bta Mameni\u0161kien\u0117","raw_affiliation_strings":["Clinic of Neurology and Neurosurgery, Medical Faculty, Vilnius University","Neurology Centre, Vilnius University Hospital Santari\u0161ki\u0173 Klinikos, Vilnius, Lithuania","UCB Pharma (B.M.), Slough, UK","UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinic of Neurology and Neurosurgery, Medical Faculty, Vilnius University","institution_ids":["https://openalex.org/I173212132"]},{"raw_affiliation_string":"Neurology Centre, Vilnius University Hospital Santari\u0161ki\u0173 Klinikos, Vilnius, Lithuania","institution_ids":["https://openalex.org/I4210161607"]},{"raw_affiliation_string":"UCB Pharma (B.M.), Slough, UK","institution_ids":["https://openalex.org/I4210134054"]},{"raw_affiliation_string":"UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065039250","display_name":"Pier Paolo Quarato","orcid":"https://orcid.org/0000-0002-4082-7948","observed_orcids":["https://orcid.org/0000-0002-4082-7948"]},"institutions":[{"id":"https://openalex.org/I3018288129","display_name":"Istituto Neurologico Mediterraneo","ror":"https://ror.org/00cpb6264","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I3018288129","https://openalex.org/I4210153126"]},{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]},{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]}],"countries":["GB","IT","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Pier Paolo Quarato","raw_affiliation_strings":["IRCCS Instituto Neurologico, Centro per la Chirurgia dell'Epilessia, Pozzilli, Italy","UCB Pharma (B.M.), Slough, UK","UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IRCCS Instituto Neurologico, Centro per la Chirurgia dell'Epilessia, Pozzilli, Italy","institution_ids":["https://openalex.org/I3018288129"]},{"raw_affiliation_string":"UCB Pharma (B.M.), Slough, UK","institution_ids":["https://openalex.org/I4210134054"]},{"raw_affiliation_string":"UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030901765","display_name":"Pavel Klein","orcid":"https://orcid.org/0000-0001-7244-3722","observed_orcids":["https://orcid.org/0000-0001-7244-3722"]},"institutions":[{"id":"https://openalex.org/I4210124000","display_name":"Mid Atlantic Epilepsy and Sleep Center","ror":"https://ror.org/036vyc207","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210124000"]},{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]},{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]}],"countries":["GB","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Pavel Klein","raw_affiliation_strings":["Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD","UCB Pharma (B.M.), Slough, UK","UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD","institution_ids":["https://openalex.org/I4210124000"]},{"raw_affiliation_string":"UCB Pharma (B.M.), Slough, UK","institution_ids":["https://openalex.org/I4210134054"]},{"raw_affiliation_string":"UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090758699","display_name":"Jessica Gamage","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]},{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]}],"countries":["GB","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jessica Gamage","raw_affiliation_strings":["QXV Communications, Macclesfield, UK","UCB Pharma (B.M.), Slough, UK","UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"QXV Communications, Macclesfield, UK","institution_ids":[]},{"raw_affiliation_string":"UCB Pharma (B.M.), Slough, UK","institution_ids":["https://openalex.org/I4210134054"]},{"raw_affiliation_string":"UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060718788","display_name":"Jimmy Schiemann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]},{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]}],"countries":["GB","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jimmy Schiemann","raw_affiliation_strings":["UCB Pharma (B.M.), Slough, UK","UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma (B.M.), Slough, UK","institution_ids":["https://openalex.org/I4210134054"]},{"raw_affiliation_string":"UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016784917","display_name":"Martin E. Johnson","orcid":"https://orcid.org/0000-0002-8398-5436","observed_orcids":["https://orcid.org/0000-0002-8398-5436"]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]},{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]}],"countries":["GB","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Martin E. Johnson","raw_affiliation_strings":["UCB Pharma (B.M.), Slough, UK","UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma (B.M.), Slough, UK","institution_ids":["https://openalex.org/I4210134054"]},{"raw_affiliation_string":"UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027558784","display_name":"John Whitesides","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]},{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]}],"countries":["GB","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"John Whitesides","raw_affiliation_strings":["UCB Pharma (B.M.), Slough, UK","UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma (B.M.), Slough, UK","institution_ids":["https://openalex.org/I4210134054"]},{"raw_affiliation_string":"UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062135612","display_name":"Belinda McDonough","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]},{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]}],"countries":["GB","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Belinda McDonough","raw_affiliation_strings":["UCB Pharma (B.M.), Slough, UK","UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma (B.M.), Slough, UK","institution_ids":["https://openalex.org/I4210134054"]},{"raw_affiliation_string":"UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5051188115","display_name":"Klaus Eckhardt","orcid":"https://orcid.org/0000-0002-5030-0971","observed_orcids":["https://orcid.org/0000-0002-5030-0971"]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]},{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]}],"countries":["GB","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Klaus Eckhardt","raw_affiliation_strings":["UCB Pharma (B.M.), Slough, UK","UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma (B.M.), Slough, UK","institution_ids":["https://openalex.org/I4210134054"]},{"raw_affiliation_string":"UCB Pharma (J.S., M.E.J., J.W., K.E.), Raleigh, NC","institution_ids":["https://openalex.org/I4210127098"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5061862920"],"corresponding_institution_ids":["https://openalex.org/I4210127098","https://openalex.org/I4210134054","https://openalex.org/I881427289"],"apc_list":null,"apc_paid":null,"fwci":7.3061,"has_fulltext":true,"cited_by_count":120,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.98080359,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":100},"biblio":{"volume":"87","issue":"3","first_page":"314","last_page":"323"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12229","display_name":"Pharmacological Effects and Toxicity Studies","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12267","display_name":"Diet and metabolism studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brivaracetam","display_name":"brivaracetam","score":0.9909999966621399},{"id":"https://openalex.org/keywords/focal-seizures","display_name":"focal seizures","score":0.9789999723434448},{"id":"https://openalex.org/keywords/adjunctive-antiepileptic-therapy","display_name":"adjunctive antiepileptic therapy","score":0.8700000047683716},{"id":"https://openalex.org/keywords/seizure-frequency-reduction","display_name":"seizure frequency reduction","score":0.8429999947547913},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.8809999823570251},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.765999972820282},{"id":"https://openalex.org/keywords/levetiracetam","display_name":"levetiracetam","score":0.625},{"id":"https://openalex.org/keywords/antiepileptic-drug-resistance","display_name":"antiepileptic drug resistance","score":0.6290000081062317},{"id":"https://openalex.org/keywords/adult-epilepsy","display_name":"adults with epilepsy","score":0.7360000014305115},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.32100000977516174}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8260599374771118},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7849265933036804},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5959723591804504},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5954282283782959},{"id":"https://openalex.org/C2777332695","wikidata":"https://www.wikidata.org/wiki/Q417227","display_name":"Levetiracetam","level":3,"score":0.574134349822998},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5608258843421936},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5082835555076599},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.4629977345466614},{"id":"https://openalex.org/C3018162438","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Adjunctive treatment","level":2,"score":0.4552447199821472},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.4332354962825775},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.4030683636665344},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3554641604423523},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.32721763849258423},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077287","descriptor_name":"Levetiracetam","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000927","descriptor_name":"Anticonvulsants","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004828","descriptor_name":"Epilepsies, Partial","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010889","descriptor_name":"Piracetam","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010889","descriptor_name":"Piracetam","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D010889","descriptor_name":"Piracetam","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011760","descriptor_name":"Pyrrolidinones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011760","descriptor_name":"Pyrrolidinones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011760","descriptor_name":"Pyrrolidinones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012640","descriptor_name":"Seizures","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1212/wnl.0000000000002864","doi":"https://doi.org/10.1212/wnl.0000000000002864","is_oa":true,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000002864","pdf_url":"https://n.neurology.org/content/neurology/87/3/314.full.pdf","source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:3931609","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4955277","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:4955277","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4955277/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"Text"},{"id":"pmid:27335114","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27335114","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":{"id":"doi:10.1212/wnl.0000000000002864","doi":"https://doi.org/10.1212/wnl.0000000000002864","is_oa":true,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000002864","pdf_url":"https://n.neurology.org/content/neurology/87/3/314.full.pdf","source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320337846","display_name":"UCB Pharma","ror":"https://ror.org/01n029866"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2472978162.pdf","grobid_xml":"https://content.openalex.org/works/W2472978162.grobid-xml"},"referenced_works_count":39,"referenced_works":["https://openalex.org/W1498064496","https://openalex.org/W1502126985","https://openalex.org/W1554576051","https://openalex.org/W1565364436","https://openalex.org/W1576738253","https://openalex.org/W1591680113","https://openalex.org/W1886650273","https://openalex.org/W1916788136","https://openalex.org/W1974809694","https://openalex.org/W1979558709","https://openalex.org/W1990267823","https://openalex.org/W1992028227","https://openalex.org/W2017493593","https://openalex.org/W2025490080","https://openalex.org/W2032745894","https://openalex.org/W2032960068","https://openalex.org/W2037534050","https://openalex.org/W2038159150","https://openalex.org/W2051013481","https://openalex.org/W2052676471","https://openalex.org/W2054429118","https://openalex.org/W2055249621","https://openalex.org/W2079669581","https://openalex.org/W2083702687","https://openalex.org/W2095271866","https://openalex.org/W2099690974","https://openalex.org/W2107427879","https://openalex.org/W2119181594","https://openalex.org/W2122573606","https://openalex.org/W2134247911","https://openalex.org/W2168143783","https://openalex.org/W2234571981","https://openalex.org/W2284268250","https://openalex.org/W2416867523","https://openalex.org/W2419659369","https://openalex.org/W2593609918","https://openalex.org/W2594846048","https://openalex.org/W2613020156","https://openalex.org/W2809101690"],"related_works":["https://openalex.org/W1916788136","https://openalex.org/W2415570348","https://openalex.org/W1490310274","https://openalex.org/W2134247911","https://openalex.org/W2419659369","https://openalex.org/W1502126985","https://openalex.org/W6902342975","https://openalex.org/W2507507548","https://openalex.org/W2738242679","https://openalex.org/W2480004538"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"assess":[2],"the":[3,90,95,170,181],"efficacy,":[4],"safety,":[5],"and":[6,65,78,129,155,196,209,216,243,253,283],"tolerability":[7],"of":[8,20,61],"adjunctive":[9,271],"brivaracetam":[10],"(BRV),":[11],"a":[12,79],"selective,":[13],"high-affinity":[14],"ligand":[15],"for":[16,18,115,123,132,164],"SV2A,":[17],"treatment":[19,81],"partial-onset":[21],"(focal)":[22],"seizures":[23],"(POS)":[24],"in":[25,56,107,223,257,275,279],"adults.":[26],"METHODS:":[27],"Data":[28],"were":[29,87,187,204,230],"pooled":[30],"from":[31,89],"patients":[32,213,225],"(aged":[33],"16-80":[34],"years)":[35],"with":[36,259,281],"POS":[37,109,277],"uncontrolled":[38,284],"by":[39,69,189,206],"1":[40],"to":[41,178],"2":[42],"antiepileptic":[43],"drugs":[44],"receiving":[45,84,214,219],"BRV":[46,62,191,215,227,250,272],"50,":[47],"100,":[48],"or":[49,52],"200":[50,133],"mg/d":[51,117,125,134],"placebo,":[53],"without":[54],"titration,":[55],"3":[57,212],"phase":[58],"III":[59],"studies":[60,73],"(NCT00490035,":[63],"NCT00464269,":[64],"NCT01261325,":[66],"ClinicalTrials.gov,":[67],"funded":[68],"UCB":[70],"Pharma).":[71],"The":[72,138],"had":[74],"an":[75],"8-week":[76],"baseline":[77],"12-week":[80],"period.":[82],"Patients":[83],"concomitant":[85],"levetiracetam":[86],"excluded":[88],"efficacy":[91,96],"pool.":[92],"RESULTS:":[93],"In":[94],"population":[97,172],"(n":[98,174,193,199],"=":[99,119,147,160,175,194,200],"1,160),":[100],"reduction":[101],"over":[102],"placebo":[103,165,198,220],"(95%":[104],"confidence":[105],"interval)":[106],"baseline-adjusted":[108],"frequency/28":[110],"days":[111],"was":[112,142,251],"19.5%":[113],"(8.0%-29.6%)":[114],"50":[116],"(p":[118,126,135,166],"0.0015),":[120,148],"24.4%":[121],"(16.8%-31.2%)":[122],"100":[124],"<":[127,136,153,167],"0.00001),":[128,154],"24.0%":[130],"(15.3%-31.8%)":[131],"0.00001).":[137],"\u226550%":[139],"responder":[140],"rate":[141],"34.2%":[143],"(50":[144],"mg/d,":[145,151,158],"p":[146,152,159],"39.5%":[149],"(100":[150],"37.8%":[156],"(200":[157],"0.00003)":[161],"vs":[162,233,237,241,246],"20.3%":[163],"0.01).":[168],"Across":[169],"safety":[171],"groups":[173],"1,262),":[176],"90.0%":[177],"93.9%":[179],"completed":[180],"studies.":[182],"Treatment-emergent":[183],"adverse":[184],"events":[185],"(TEAEs)":[186],"reported":[188,205],"68.0%":[190],"overall":[192],"803)":[195],"62.1%":[197],"459).":[201],"Serious":[202],"TEAEs":[203,222],"3.0%":[207],"(BRV)":[208],"2.8%":[210],"(placebo);":[211],"one":[217],"patient":[218],"died.":[221],"\u22655%":[224],"taking":[226],"(vs":[228],"placebo)":[229],"somnolence":[231],"(15.2%":[232],"8.5%),":[234],"dizziness":[235],"(11.2%":[236],"7.2%),":[238],"headache":[239],"(9.6%":[240],"10.2%),":[242],"fatigue":[244],"(8.7%":[245],"3.7%).":[247],"CONCLUSIONS:":[248],"Adjunctive":[249],"effective":[252,274],"generally":[254],"well":[255],"tolerated":[256],"adults":[258,280],"POS.":[260],"CLASSIFICATION":[261],"OF":[262],"EVIDENCE:":[263],"This":[264],"analysis":[265],"provides":[266],"Class":[267],"I":[268],"evidence":[269],"that":[270],"is":[273],"reducing":[276],"frequency":[278],"epilepsy":[282],"seizures.":[285]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2472978162","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":11},{"year":2024,"cited_by_count":11},{"year":2023,"cited_by_count":11},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":14},{"year":2020,"cited_by_count":20},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":12},{"year":2017,"cited_by_count":16},{"year":2016,"cited_by_count":4}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-07-22T00:00:00"}
